3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Rectal Neoplasms
1
Neuroblastoma
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Liver Neoplasms
1
Laryngeal Diseases
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Irinotecan
4
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pembrolizumab
2
cobimetinib
2
Sunitinib
2
Sorafenib
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
repotrectinib
1
pralsetinib
1
osimertinib
1
lutetium Lu 177 dotatate
1
linifanib
1
guadecitabine
1
golotimod
1
genexol-PM
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
capmatinib
×
Gastrointestinal
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled